ALX Oncology to present CD47 biomarker data for evorpacept at SITC

Clinical-stage biotech ALX Oncology (ALXO) is set to present updated Phase 2 data for its lead candidate, evorpacept, in HER2-positive gastric cancer at the SITC 40th Annual Meeting on November 8. This comes as the company's stock has surged over 250% in the past six months, nearing its 52-week high, despite a recent Q2 2025 EPS miss and concerns over its rapid cash burn rate. ALX Oncology is also advancing a new Phase 1 candidate, ALX2004, and analysts maintain a positive outlook, reflecting ongoing pipeline development amidst financial scrutiny.

Analysis

ALX Oncology (ALXO), a clinical-stage biotech, faces a pivotal moment with the upcoming presentation of updated Phase 2 data for its lead candidate, evorpacept, at the SITC meeting on November 8. This catalyst follows a significant stock surge of over 250% in the past six months, pushing the valuation near its 52-week high. However, this bullish momentum is contrasted by concerning financial metrics; the company is rapidly burning through cash and recently missed Q2 2025 earnings estimates with an EPS of -0.49 USD against a -0.43 USD forecast. While ALXO maintains a strong liquidity position with a current ratio of 4.52 and more cash than debt, the burn rate remains a key risk. Pipeline diversification is in its early stages, with a second candidate, ALX2004, having just entered a Phase 1 trial. Analyst price targets of $2-$3 per share suggest a continued focus on the clinical potential of evorpacept, framing the upcoming data release as a critical validation event for the stock's recent performance.

Key Decisions for Investors

• Investors should treat the November 8 data presentation for evorpacept as a major binary event, as its outcome will be critical in justifying the stock's recent 250% appreciation.
• Given the rapid cash burn and recent earnings miss, it is prudent to assess the company's financial runway, as the risk of a dilutive equity offering may increase, especially in the event of mixed or negative clinical results.
• The significant run-up in ALXO's share price suggests a high level of optimism is already priced in, increasing downside risk should the ASPEN-06 trial data fail to meet heightened market expectations.